Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
Patients will receive SGX945 as a twice-weekly 4-minute intravenous (IV) infusion for 4 weeks, followed by 4 weeks of follow-up.On Thursday, Soligenix Inc. (NASDAQ:SNGX) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 (dusquetide) for Behçet's Disease, an inflammatory disorder of the blood vessels (vasculitis).
週四，soligenix, inc.（納斯達克：SNGX）開啓了其DUS-AUBD-01第二階段研究的患者招募，該研究評估SGX945（dusquetide）用於貝赫切特病，這是一種血管的炎症疾病（血管炎）。
The company looks forward to completing enrollment and announcing study results in the first half of 2025.
該公司期待在2025年上半年完成招募並宣佈研究結果。
The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate Behçet's Disease and active oral and/or genital ulcers.
SGX945的臨床試驗將是一項開放標籤研究，預計招募約25名年齡在18歲或以上的輕度至中度貝赫切特病患者，以及活躍的口腔和/或生殖器潰瘍。
Patients will receive SGX945 as a twice-weekly 4-minute intravenous (IV) infusion for 4 weeks, followed by 4 weeks of follow-up.
患者將接受SGX945，每週兩次，靜脈注射（IV）4分鐘，持續4周，隨後進行4周的隨訪。
Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance, and patient reported quality of life assessments.
療效終點將包括病竈清除的程度、病竈清除的時間表和患者報告的生活質量評估。
Dusquetide, the active ingredient in SGX945 (Behçet's Disease) and SGX942 (oral mucositis), is an innate defense regulator (IDR), a new class of short, synthetic peptides.
Dusquetide是SGX945（貝赫切特病）和SGX942（口腔粘膜炎）的活性成分，是一種先天免疫調節劑（IDR），是一類新的短鏈合成肽。
Dusquetide has demonstrated safety and tolerability in a Phase 1 study in 84 healthy human volunteers.
Dusquetide在84名健康人蔘與的第一階段研究中表現出了安全性和耐受性。
In Phase 2 and 3 clinical studies with dusquetide in over 350 subjects with oral mucositis due to chemoradiation therapy for head and neck cancer, positive efficacy results were demonstrated, including potential long-term ancillary benefits.
在對超過350名因頭頸癌接受化放療而出現口腔粘膜炎的受試者進行的第二和第三階段臨床研究中，dusquetide展示了積極的療效結果，包括潛在的長期附帶益處。
There are approximately 18,000 known cases of Behçet's Disease in the U.S., 350,000 in Turkey, and over 50,000 in Europe. There are as many as 1 million people worldwide living with Behçet's Disease.
在美國大約有18,000例已知的白塞病病例，在土耳其有350,000例，在歐洲有超過50,000例。全球生活在白塞病患者中可能有100萬人。
In July, The Princeton, New Jersey-based company announced an interim update on the open-label, investigator-initiated study (IIS) evaluating extended Hybryte treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL).
在7月份，這家位於新澤西州普林斯頓的公司宣佈了對開放標籤的、研究者發起的研究（IIS）的中期更新，該研究評估了對早期皮膚T細胞淋巴瘤（CTCL）患者的延長Hybryte治療，時間長達12個月。
Patients have responded positively to HyBryte therapy. Three of the four subjects who have completed at least 12 weeks of therapy already achieved "Treatment Success."
患者對Hybryte治療反應積極。在完成至少12周治療的四名受試者中，有三名已經達到了「治療成功」。
Price Action: At the last check on Thursday, SNGX stock traded higher by 1.10% to $3.67 premarket.
價格動態：週四最後檢查時，SNGX股票在盤前交易中上漲了1.10%，至3.67美元。
- Boeing Reportedly Plans Furloughs: What's Going On
- 波音 reportedly 計劃裁員：發生了什麼事
